CD274 and neoplasm: This enabled tumour growth control and the subsequent evaluation of a novel immunotherapy approach using anti-PD-L1 and the oncolytic adenovirus Ad5/3-E2F-D24-hTNFα-IRES-hIL2 (TILT-123) in a virus replication permissive setting.